MAP2K7 and melanoma: Phase 1 Study of the BRAF-Inhibitor Dabrafenib ± MEK Inhibitor Trametinib in Combination With Ipilimumab for V600E/K Mutation-Positive Metastatic or Unresectable Melanoma